Risk assessment in #BreastCancer is essential for clinical decisions. The future of predicting #RiskofRecurrence relies on a personalized approach, using diverse tools to accurately gauge recurrence risk and provide tailored patient care.
Lilly Oncology International
制药业
Channel for the Professional Oncology & Hematology Communities. Follow us for updates.
关于我们
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, including transforming the most difficult-to-treat cancers into manageable diseases. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. When you engage with Lilly Oncology International on LinkedIn (and any other of Lilly's social media channels), you are agreeing to these Community Guidelines: https://e.lilly/3XKThyc You are also agreeing to the terms and conditions, or other legal notices provided by Lilly and those of LinkedIn.
- 网站
-
www.lilly.com/disease-areas/cancer
Lilly Oncology International的外部链接
- 所属行业
- 制药业
- 规模
- 1,001-5,000 人
- 总部
- Indianapolis
- 领域
- Oncology and Biopharmaceuticals
动态
-
Learn from Prof. Matteo Lambertini about the significance of ctDNA monitoring as a tool for predicting the #RiskOfRecurrence. Watch now and stay tuned for more updates!
-
Don't miss out on the benefits of CME on #HematologicalMalignancy for your practice. Learn more about the latest in #Hematology at #ASH24.
-
-
Dr. Rodrigo Sánchez-Bayona highlights the tools used to predict the #RiskOfRecurrence emphasizing the importance of MRD detection. Watch to understand how this could improve risk assessment.
-
How do you identify which patients with #HematologicalMalignancy have unmet needs and may benefit from additional supportive care in your clinical practice?
-
-
Curious about how to assess the #RiskOfRecurrence? Dr. Rodrigo Sánchez-Bayona discusses key factors involved for determining recurrence risk. Watch now and stay tuned for more updates!
-
Curious about the prognosis for patients with relapsed/refractory #MantleCellLymphoma? How does the literature about #MCL overall survival compare with your clinical observations?
-
-
To improve survivorship care, using patient-reported outcomes (PROs) is highly effective in identifying the #RiskofRecurrence in #BreastCancer. Cancer recurrence significantly impacts patient survival, with a 37% risk of death after local recurrence at 5 years.1 In a study of 88 recurrent cases and 96 non-recurrent cases, the importance of PROs related to general health and its link to cancer recurrence was established.2 How are you incorporating these insights into your clinical practice?